C About
Chai Discovery develops generative AI models focused on de novo molecular design for drug discovery. Their core technology utilizes a proprietary transformer-based architecture to predict and engineer biomolecular interactions, enabling the creation of novel protein and small molecule therapeutics. Recently securing $130M in Series B funding, Chai Discovery targets the pharmaceutical industry with a platform aimed at accelerating the identification of promising drug candidates.
Focus Areas
Technology Focus
drug discovery foundation models
Quick Stats
- Founded
- 2024
- Status
- private
- Type
- startup
Explore More
Similar Companies
Ranked by shared focus areas, technology, and location.
Latent Labs
London, United Kingdom
88%
2 shared categories
2 shared AI types
Drug DiscoveryAI Research
BioAge Labs
Richmond, United States
82%
2 shared categories
1 shared AI type
Same country
Drug DiscoveryAI Research
Atomic AI
San Francisco, United States
82%
2 shared categories
1 shared AI type
Same country
Drug DiscoveryAI Research
Genesis Therapeutics
Burlingame, United States
82%
2 shared categories
1 shared AI type
Same country
Drug DiscoveryAI Research